Market Closed -
Other stock markets
|
|
5-day change | 1st Jan Change | |
40.59 USD | -0.73% | +1.83% | -18.61% |
Nov. 15 | QIAGEN N.V Launches TissueLyser III and RNeasy PowerMax Soil Pro Kit for Improved Sample Processing and RNAisolation | CI |
Nov. 15 | QIAGEN NV : Jefferies reiterates its Neutral rating | ZD |
Financials (USD)
Sales 2023 * | 1,963 M | Sales 2024 * | 2,065 M | Capitalization | 9,262 M |
---|---|---|---|---|---|
Net income 2023 * | 345 M | Net income 2024 * | 401 M | EV / Sales 2023 * | 5,07x |
Net Debt 2023 * | 685 M | Net Debt 2024 * | 197 M | EV / Sales 2024 * | 4,58x |
P/E ratio 2023 * | 27,0x | P/E ratio 2024 * | 22,9x | Employees | 6,000 |
Yield 2023 * | - | Yield 2024 * | - | Free-Float | 98.49% |
More Fundamentals
* Assessed data
More news
More press releases
More news
1 day | -0.73% | ||
1 week | +1.83% | ||
Current month | +8.44% | ||
1 month | +12.41% | ||
3 months | -9.21% | ||
6 months | -11.89% | ||
Current year | -18.61% |
1 week
40.57
41.23

1 month
34.74
41.23

Current year
34.74
51.18

1 year
34.74
51.18

3 years
34.74
59.00

5 years
25.04
59.00

10 years
20.21
59.00

Managers | Title | Age | Since |
---|---|---|---|
Thierry Bernard
CEO | Chief Executive Officer | 59 | 2015 |
Metin Colpan
FOU | Founder | 68 | 1996 |
Roland Sackers
DFI | Director of Finance/CFO | 55 | 1998 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 73 | 2011 | |
Metin Colpan
FOU | Founder | 68 | 1996 |
Thomas Ebeling
BRD | Director/Board Member | 64 | 2021 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
9.74% | 673 M€ | +5.92% | ||
9.74% | 6 M€ | +6.42% | - | |
9.70% | 77 M€ | 0.00% | ||
4.32% | 4 M€ | -20.73% | ||
4.32% | 77 M€ | -17.23% |
Date | Price | Change | Volume |
---|---|---|---|
23-11-27 | 40.59 | -0.73% | 1,523,100 |
23-11-24 | 40.89 | +0.59% | 387,948 |
23-11-22 | 40.65 | +0.74% | 1,381,307 |
23-11-21 | 40.35 | +1.23% | 1,224,777 |
Delayed Quote Nyse, November 27, 2023 at 04:00 pm EST
More quotes
Qiagen N.V. is one of the world's leaders in designing, manufacturing, and marketing chemical products for the isolation, purification, and manipulation of DNA (deoxyribonucleic acid) and RNA (ribonucleic acid).
In 2022, the group developed more than 500 core consumable products and automated solutions through its over 35 locations worldwide.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (34.2%), the United States (42.5%), America (4.1%) and other (19.2%).
Calendar
Trading Rating :
Investor Rating :
ESG Refinitiv :
A
Sell
Buy

Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
40.59USD
Average target price
48.47USD
Spread / Average Target
+19.41%
EPS Revisions
1st Jan change | Capi. (M$) | |
---|---|---|
-18.61% | 9 262 M $ | |
+66.85% | 40 453 M $ | |
+2.85% | 38 458 M $ | |
-56.73% | 29 633 M $ | |
-23.90% | 29 066 M $ | |
+38.69% | 22 180 M $ | |
-33.01% | 19 978 M $ | |
+1.43% | 17 370 M $ | |
-16.90% | 10 860 M $ | |
-24.88% | 9 846 M $ |